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Collagen arthritis can be induced readily in many strains of rats by immunizing 
them  with  heterologous or  homologous native  type II  collagen emulsified in 
incomplete Freund's adjuvant (1).  This disease, which is  characterized by the 
development of both cellular and humoral immune response to type II collagen 
(2-4), can be passively transferred by sensitized spleen and lymph node cells (5) 
as well as IgG antibodies to type II collagen (6). These findings are consistent 
with the proposal that collagen arthritis is the result of immunologic hypersen- 
sitivity to type II collagen. In a recent report, Trentham et al. (7) showed that 
rats with adjuvant arthritis exhibited both humoral and cellular sensitivities to 
homologous type II collagen, and suggested that an autoimmune response  to 
type I!  collagen is  a  common feature to  both  collagen arthritis and adjuvant 
arthritis. However, subsequent studies (8,  9)  have produced conflicting results 
that shed some doubt on this exciting concept, and the discrepancies need further 
clarification. 
The present study was intended to determine if an autoimmune response to 
type II collagen is responsible for the induction of both collagen arthritis and 
adjuvant arthritis by  using a  relatively new  immunosuppressive agent,  cyclos- 
porin, which has been  shown to be capable of inducing specific immunologic 
tolerance in several in vivo and in vitro conditions (10,  1 I). 
Materials and Methods 
Animals.  Outbred female Sprague-Dawley rats  were purchased  from Japan Charles 
River Breeding Laboratories, Kanagawa,  Japan. They were allowed 1 wk to adapt to their 
environment and were used at 6 wk old, weighing 130-160  g at the start of the present 
experiment.  All the animals received standard laboratory chow and water ad libitum. 
Preparation of Type II Collagen and Production of Collagen Arthritis.  Type II collagen was 
isolated and purified from bovine articular cartilage  as previously described  (1). The 
purity was assessed as described elsewhere (12). Lyophilized type II collagen was dissolved 
in 0.I  M acetic acid at a concentration of 3 mg/ml. Equal volumes of collagen solution 
and incomplete Freund's adjuvant (Difco Laboratories, Inc., Detroit, MI) were emulsified 
using a homogenizer  (Polytron  PT  10-35; Kinematica, Lucerne, Switzerland) and kept 
cold with an ice bath. Collagen arthritis was produced by intradermal  injection of 1 ml of 
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the cold emulsion at several sites on the back and at one or two sites into the base of the 
tail. 
Production of  Adjuvant Arthritis.  Adjuvant arthritis was produced by a single intradermai 
injection of 0.1 ml of complete Freund's adjuvant (CFA)  1 at the base of the tail. CFA was 
prepared by adding dried, heat-killed Mycobacterium butyricum (Difco Laboratories, Inc.), 
which was finely powdered with a mortar and pestle, to mineral oil (Sigma Chemical Co., 
St. Louis, MO) at a concentration of 10 mg/ml. 
Treatment with Cyclosporin.  Cyclosporin (kindly provided by Sandoz Ltd., Basel, Switz- 
erland) was dissolved in pure olive oil at a concentration of 25 mg/mi by heating in a 
water bath to 65°C. It was freshly prepared every 3 d. Cyclosporin was given subcutane- 
ously under light ether anesthesia at a dose of 25 mg/kg per day for 14 d beginning on 
the same day as the injection of type II collagen or CFA. The dose was adjusted according 
to the daily body weight. Control rats received olive oil alone. Cyclosporin-treated and 
control rats were handled identically for administration of the agent and the solvent. 
Assessment of Arthritis.  Rats were examined daily for 6-7 wk after the injection of type 
II collagen or CFA to record the day of onset and the severity of arthritis. The lesions of 
the  four paws  were  each  graded  from  0  to  4  according to  the  increasing extent of 
periarticular erythema and swelling as well as joint deformity, as described previously 
(13). The maximum possible score was 16. 
Immune Responses to Type II Collagen.  Delayed-type hypersensitivity (DTH) skin testing 
was performed as described by Griffiths et al. (14) using 50 t~g of type II collagen in 0.05 
M Tris-HCl buffer, pH 7.2, containing 0.2 M NaCI. The responses were read at 48 h. 
Serum antibodies to type II collagen were measured by the enzyme-linked immunoassay 
technique as described elsewhere (12), which was adapted from the methods of Voller et 
al. (15). The quantity of IgG anti-type II collagen antibody was expressed as milligrams 
per  100 ml ofserum by comparison with standard curves obtained from a purified rat 
anti-type II collagen antibody control. 
Antibodies  to  type  II  collagen  were  purified  by  affinity chromatography  (16)  on 
cyanogen bromide (CNBr)-activated Sepharose 4B (Pharmacia Fine Chemicals AB, Upps- 
ala, Sweden). Briefly, CNBr-activated Sepharose 4B (2 g dry weight) was washed several 
times with 400 mi of 1 mM HCI on a sintered glass funnel and finally with coupling buffer 
(0.1  M NaHCOs buffer, pH 8.3, containing 0.5 M NaCI).  The activated Sepharose was 
added to the collagen solution (35 mg type II collagen in 14 ml of coupling buffer). The 
suspension was stirred gently at 4°C for I6 h. 2 ml of 1 M ethanotamine was added and 
incubation was continued for 1 h. The coilagen-Sepharose conjugate was washed alter- 
nately with phosphate-buffered saline (PBS) and 0.2 M glycine-HCI buffer, pH 2.5, for 
three cycles. Then the collagen-Sepharose conjugate was equilibrated with PBS and 6 ml 
of antisera obtained from arthritic rats 4 wk after immunization with type II collagen was 
added. After incubation overnight at 4°C, the suspension was packed in a  1 ×  10-cm 
column and washed with PBS until no protein could be detected in the wash  fluid by 
spectrophotometry. The antibodies bound to the affinity column was eluted with 0.2 M 
glycine-HCI buffer, pH 2.5, dialyzed against several changes of  cold PBS, and concentrated 
by pressure dialysis. The quantity of IgG antibody was measured by radial immunodiffu- 
sion methods using the Miles rat IgG kit (Miles Laboratories, Inc., Elkhart, IN). 
Statistics.  Continuous variables were analyzed by their group means (Student's t test) 
and dichotomous variables by their proportionate group frequencies (chi-square test). P 
values <0.05 were considered to be statistically significant. 
Results 
Effect  of Cyclosporin  on Collagen Arthritis and Immune Responses  to Type H  Colla- 
gen.  Rats were immunized with  1.5  mg of type II collagen on day 0  and were 
treated with cyclosporin or olive oil for 14 d  beginning on the day of immuni- 
zation.  An  inflammatory  polyarthritis  developed  in  89%  of type  II  collagen- 
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immunized, non-cyciosporin-treated rats.  Daily treatment with cyclosporin at a 
dose  of 25  mg/kg  for  14  d  gave  complete  suppression  of arthritis  induction 
during an observation period of 45 d  (Table I). 
Serum antibody levels to type II collagen were measured on day 21 and DTH 
skin testing was performed on day 25. Olive-oil-treated control rats showed high 
antibody levels and strong positive skin test responses to type II collagen, whereas 
very weak antibody responses and negative to weak skin test responses to type II 
collagen could be detected in the rats treated with cyclosporin. These results are 
in accord with our previous report (12). 
Effect of Cyclosporin on Adjuvant Arthritis  and Immune Responses to Type H Colla- 
gen.  An  inflammatory  polyarthritis  was  produced  in  all  CFA-injected,  non- 
cyclosporin-treated rats. None of the cyclosporin-treated animals manifested any 
evidence of disease, in accord with a previous report by Borel et al. (17). 
In  adjuvant  arthritic  rats,  serum  antibody  levels  to  type  II  collagen  were 
measured on day 21  or 38 and  DTH  skin testing was performed on day 25 or 
42.  Not  only cyclosporin-treated rats  but  also  adjuvant  arthritic  rats  showed 
almost no antibody responses and no DTH skin test responses to type II collagen, 
even well after the disease onset (Table II). 
Rechallenge  Studies  of the Cyclosporin-protected Rats.  In the preceding sections, 
it was demonstrated that daily treatment with cyclosporin for the first 14 d  gave 
complete suppression of the arthritogenic reaction produced by type II collagen 
or CFA. In the next experiment, we investigated the specificity of the cyclosporin- 
induced  immunologic  unresponsiveness  by  rechallenging  the  cyclosporin-pro- 
tected rats with either type II collagen or CFA on day 17 in an identical manner 
as that used for the primary challenge. As shown in Table III, type II collagen- 
immunized, cyclosporin-protected rats  did not develop arthritis  in response to 
reimmunization  with  type  II  collagen,  whereas  they  did  develop  arthritis  in 
response  to a  subsequent  injection of CFA,  though  the severity of arthritis in 
these rats was weakened as compared with that of adjuvant arthritic rats in Table 
TABLE  I 
Effect of Cyclosporin on Collagen Arthritis 
Group 
Cyclosporin  Olive oil 
P values 
Rats were immunized with 1.5 mg of type II collagen on day 0 and 
treated with cyclosporin (25 mg]kg) or olive oil for 14 d. 
* Expressed as the mean of maximum arthritic indices ± SEM for arthritic 
rats only. 
* Based on arthritic rats only (mean ± SEM). 
! Antibody levels to type II  collagen were measured on day 21  using 
enzyme-linked immunoassay system and expressed as milligrams of IgG 
anti-type II collagen antibody per 100 ml of serum (mean ± SEM). 
I  r  Pe formed on day 25 and expressed as the mean :k SEM diameter of 
induration (millimeters). 
Incidence of arthritis  0/14 (0%)  17/19 (89%)  <0.001 
Arthritic index*  --  6.7 ± 0.6 
Day of onset*  --  10.2 ± 0.2 
Antibody level  f  0.17 ± 0.08  108.39  ± 14.14  <0.001 
DTH skin reaction I  3.1 ± 0.8  5.6 ± 0.3  <0.005 KAIBARA ET  AL. 
TABLE  II 
Effect of Cyclosporin on Adjuvant Arthritis 
Group 
Cyclosporin  Olive oil 
P values 
Incidence of arthritis  0/10 (0%)  20/20 (100%) 
Arthritic index  --  13.0 ± 0.5 
Day of onset  --  9.7 ± 0.3 
Antibody level 
Day 21  <0.001  0.001  (10)* 
Day 38  ND*  0.001  (10) 
DTH skin reaction 
Day 25  0  0 (10) 
Day 42  ND  0 (10) 
<0.001 
Rats received an  injection of CFA on  day 0  and were treated with 
cyclosporin (25 mg/kg) or olive oil for 14 d. Parameters and units are 
identical to those described in Table I. 
* Parentheses indicate the  number  of rats  used  in  data  calculation if 
different from total tested. 
* Not done. 
TABLE  III 
Induction of antigen-specific Unresponsiveness  Mediated by Cyclosporin 
1391 
Type II collagen (day O) 
Cyclosporin (days 0-13) 
CFA (day 0) 
Cyclosporin (days 0-13) 
Type II colla-  CFA (day 17)  CFA (day 17)  Type II collagen 
gen (day 17)  (day 17) 
Incidence of arthritis  0/10 (0%)*  8/10 (80%)  5/16 (31%)*  10/10 (100%) 
Arthritic index  --  5.8 ±  1.4  5.6 +  1.1  10.4 ± 0.9 
Day of onset  --  18.0 ±  1.3  14.2 ±  1.3  10.6 ± 0.2 
Antibody level (day 38)  0.99 ± 0.30  1.36 ± 0.59  0.001!  111.62  ± 21.48 
DTH skin reaction (day 42)  4.7 ± 0.8  4.0 ± 0.8  01  7.0 ± 0.3 
Groups of rats were injected with type II collagen or CFA on day 0 and treated with cyclosporin 
from day 0 to 13. Rats in each group received an injection of either type II collagen or CFA on 
day 17. Parameters and units are identical to those described in Table I, except that the day of 
onset was calculated from day 17. 
* P <  0.002. 
* P <  0.003. 
~P< 0.001. 
II. On  the other  hand,  CFA-injected, cyclosporin-protected rats showed  a  sup- 
pressed  arthritogenic  reaction  in  response  to  rechallenge  with  CFA,  whereas 
their  response  to  a  subsequent  immunization  with  type  II  collagen  remained 
intact or somewhat enhanced.  Thus,  the prevention of arthritogenesis produced 
by  a  short  course  of  cyclosporin  treatment  might  be  explained  as  specific 
immunologic  unresponsiveness,  which can be defined as the situation where an 
individual displays a  functional nonreactivity to certain antigens while preserving 
reactivity to others. 
Effect of Cyclosporin Pretreatment on Collagen Arthritis and Adjuvant Arthritis.  To 
exclude the possibility that cyclosporin pretreatment  might have some nonspecific 
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took the following experiment.  The rats,  which were  treated with cyclosporin 
for 14 d  without any prior antigenic challenge, received an injection of CFA or 
type  II  collagen  after  the  withdrawal  of cyclosporin.  As  shown  in  Table  IV, 
cyclosporin-pretreated rats developed arthritis in response to a subsequent injec- 
tion  of CFA  or  type  II  collagen after the  cessation  of cyclosporin treatment, 
indicating that  it had  no  effect on  the  development of collagen arthritis  and 
adjuvant arthritis. 
Discussion 
Cyclosporin is a  fungal metabolite with profound immunosuppressive proper- 
ties. In a variety of experimental animal systems, the immunosuppressive capacity 
of cyclosporin to inhibit antibody production, allograft rejection, graft-versus- 
host reactions, and experimental autoimmune diseases has been well documented 
(17-21).  Of interest is the fact that cyclosporin is capable of inducing immuno- 
logic  tolerance  in  several  animal  models.  The  most  remarkable  results  were 
obtained with renal allograft across major histocompatibility barriers in rabbits 
(22, 23) and rats (24), from which cyclosporin was successfully withdrawn without 
subsequent  loss of the graft.  Similarly, fully allogeneic bone  marrow grafts in 
rats  were accepted  indefinitely if recipients  were  treated  for a  limited period 
postgrafting with cyclosporin (25, 26). In addition, Wang et al. (27) demonstrated 
that lymphocytes from mice sensitized with alloantigens and treated with cyclos- 
porin could not be reactivated upon exposure to the same alloantigen in mixed 
lymphocyte culture,  whereas their response  to a  third-party antigen remained 
intact. A similar observation on the nature of the specificity of tolerance induced 
by  cyclosporin  in  vitro  was  made  by  Hess  et  al.  (28),  in  agreement  with  our 
observations in vivo. 
On  the  basis  of  these  findings,  it  would  theoretically  be  possible  to  use 
cyclosporin to determine whether immunity to type II collagen plays a  critical 
role in the pathogenesis of both collagen arthritis and adjuvant arthritis. In our 
initial experiments, we attempted to induce a  state of unresponsiveness in rats 
receiving either type II  collagen or CFA concomitantly with a  14-d  course of 
TABLE IV 
Effect of Cydosporin Pretreatment on Collagen Arthritis and Adjuvant 
Arthritis 
Cyclosporin (days 0-13) 
Type II collagen 
(day 17)  CFA (day 17) 
Incidence of arthritis  8/10 (80%)  10/13 (77%) 
Arthritic index  6.5 + 1.0  8.9 ± 1.6 
Day of onset  13.1 _ 1.8  13.3 ± 0.7 
Antibody level (day 38)  90.49 ± 19.04  0.001 
DTH skin reaction (day 42)  6.8 ± 0.3  0 
Rats were treated with cyclosporin from day 0 to  13 without any prior 
antigenic challenge and received an injection of CFA or type II collagen 
on day 17. Parameters and units are identical to those described in Table 
I except that the day of onset was calculated from the day of injection of 
CFA or type II collagen. KAIBARA ET  AL.  1393 
prophylactic treatment with cyciosporin. The results in this paper clearly dem- 
onstrate  that  cyclosporin  is  able  to  completely suppress  the  development of 
arthritis in rats injected with type II collagen or CFA. This confirms the previous 
reports by us (12) and Borel et al. (17). Of note is the fact that arthritis remained 
absent even after cyclosporin was discontinued. 
To elucidate the possibility that the immunologic unresponsiveness produced 
by cyclosporin in the present experiments was antigen specific, we rechallenged 
the cyclosporin-protected rats with either type II collagen or CFA after cessation 
of cyclosporin  treatment.  Type  II  collagen-immunized, cyclosporin-protected 
rats  did  not  develop  arthritis  in  response  to  reimmunization  with  the  same 
antigen, whereas they did develop arthritis in response to a subsequent injection 
of CFA. Similarly, CFA-injected, cyclosporin-protected rats showed a suppressed 
arthritogenic reaction in response to a  subsequent injection of CFA. However, 
they developed arthritis in response to a  subsequent immunization with type II 
collagen. These results indicate that there is no cross-reactivity between type II 
collagen and the responsible immunogen in the mycobacterial adjuvant, and that 
immunologic unresponsiveness produced by cyclosporin is antigen specific. The 
alternative explanation that cyclosporin induces some long-lasting, nonspecific 
changes in the immune system seems to be unlikely, because our results showed 
that rats could develop arthritis  in response to an injection of CFA or type II 
collagen after a course of cyclosporin treatment given without any prior antigenic 
challenge, an effect that cannot be nonspecific. The fact that in the experiments 
reported here,  5  of  16  rats  receiving an  injection of CFA and a  concomitant 
prophylactic treatment with cyclosporin developed mild arthritis in response to 
rechallenge with CFA might be explained that the strong immunologic stimulus 
provided by CFA have partially overcome the suppressive effect of cyclosporin. 
As  demonstrated  in  the  results,  the  development of collagen  arthritis  was 
associated with  high levels of both humoral and  cellular immunity to type II 
collagen.  Adjuvant arthritic  rats  showed almost no antibody response and  no 
DTH  skin test response to type II  collagen even well after  the disease onset. 
Taken together, our results further indicate that immunity to type II collagen 
plays a critical role in the pathogenesis of collagen arthritis; however, its patho- 
genetic role in adjuvant arthritis is insignificant. 
Although it is difficult to compare the results reported by various investigators 
using  different  methods  to  achieve  antigen-specific  suppression,  our  results 
contradict the findings of Welles and Battisto (29), who showed that the severity 
of adjuvant arthritis in Lewis rats can be diminished by preimmunization with 
an alum flocculate of native type II collagen or intraperitoneal administration of 
antisera to type II collagen. A similar observation was made by Trentham et al. 
(30), who showed that the intravenous administrations of native type I! collagen 
with syngeneic spleen cells, either exposed or unexposed to coupling reagent, or 
native  type  II  collagen-coupled rat  erythrocytes,  can  suppress  the  severity  of 
propanediamine-induced arthritis in Lewis rats. However, no reactivity to colla- 
gen was found in propanediamine-injected rats. Therefore they postulated that 
antibodies  to  type  II  collagen  are  not  involved  in  the  initiation  of adjuvant 
arthritis and that host reactions to native type lI collagen play some role in the 
effector functions. Our results agree with those of Iizuka and Chang (9),  who 1394  COLLAGEN  ARTHRITIS AND  ADJUVANT ARTHRITIS 
showed that pretreatment of Sprague-Dawley rats with the maximal subarthri- 
togenic dose of CFA prevented the development of arthritis  in response to a 
subsequent injection of an arthritogenic dose of CFA, but had no effect on the 
development  of  collagen  arthritis  when  rats  were  immunized  with  type  II 
collagen.  Although this study might be criticized  for  lacking proof regarding 
whether type II collagen-tolerated rats might develop arthritis in response to a 
subsequent injection of CFA, its conclusion that immunity to type II collagen is 
not critical to the primary pathogenesis of adjuvant arthritis and that adjuvant 
arthritis and collagen arthritis are  distinctly different diseases is supported by 
our present data. 
The mechanism whereby cyclosporin induces specific immunologic unrespon- 
siveness is  not clear.  But,  recent studies using the in vitro  mixed lymphocyte 
reactions have demonstrated that this agent preferentially inhibits the prolifera- 
tion of primary helper T cells and the induction of cytotoxic effector lymphocytes 
while permitting the establishment of an antigen-specific suppressor mechanism 
(11,  28,  31).  These  studies  support  the  hypothesis  that  cyclosporin-induced 
tolerance may be mediated by suppressor cells. It is also suggested that such a 
mechanism might be operative in vivo as well by cardiac allografts studies in rats 
(32). 
In conclusion, we have demonstrated that specific immunologic unresponsive- 
ness can be induced by cyclosporin in the two experimental models of polyar- 
thritis, collagen arthritis and adjuvant arthritis. Rechallenge studies suggest that 
there is no cross-reactivity between type II collagen and the mycobacterial cell 
wall materials. Taken together, immune response studies indicate that immunity 
to type II collagen plays a  critical role in the pathogenesis of collagen arthritis, 
but that its pathogenetic role in adjuvant arthritis is insignificant. Unfortunately, 
our experimental model was unable to define what is the real etiologic immu- 
nogen responsible for the initiation of adjuvant arthritis. Further studies will be 
needed to answer this question. 
Summary 
Daily treatment with cyclosporin at a dose of 25 mg/kg for 14 d gave complete 
suppression of the development of collagen arthritis  and adjuvant arthritis  in 
Sprague-Dawley rats during an observation period of 45 d. To study whether 
the immunologic unresponsiveness produced by cyclosporin is antigen specific, 
we rechallenged the cyclosporin-protected rats with either type II collagen or 
complete  Freund's  adjuvant  (CFA)  after  discontinuation  of cyclosporin treat- 
ment. Type II collagen-immunized, cyclosporin-protected rats did not develop 
arthritis  in  response  to  reimmunization  with  type  II  collagen,  but,  they  did 
develop arthritis in response to a  subsequent injection of CFA. Similarly, CFA- 
injected, cyclosporin-protected rats showed a  suppressed arthritogenic reaction 
in  response  to  reinjection  of  CFA,  whereas  their  response  to  a  subsequent 
immunization with type II collagen was unaffected. On the other hand, the rats 
that were treated with cyclosporin without any prior antigenic challenge could 
develop arthritis in response to a subsequent injection of CFA or type II collagen 
after  cessation  of cyclosporin  treatment.  These  results  indicate  that  specific 
immunologic unresponsiveness can be induced by cyclosporin in the two exper- KAIBARA ET AL.  1395 
imental models of polyarthritis, collagen arthritis and adjuvant arthritis, and that 
there is no cross-reactivity between type II collagen and the mycobacterial cell 
wall components. The results further indicate that immunity to type II collagen 
plays a critical role in the pathogenesis of collagen arthritis but that its pathoge- 
netic role in adjuvant arthritis is insignificant. 
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